Analysts Set Guardian Pharmacy Services, Inc. (NYSE:GRDN) Price Target at $42.83

Shares of Guardian Pharmacy Services, Inc. (NYSE:GRDN) have been given an average rating of “Moderate Buy” by the nine brokerages that are covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $42.8333.

A number of analysts recently weighed in on the stock. Truist Financial increased their price objective on shares of Guardian Pharmacy Services from $43.00 to $47.00 and gave the stock a “buy” rating in a research report on Wednesday, June 17th. Jefferies Financial Group assumed coverage on Guardian Pharmacy Services in a research report on Monday, March 30th. They set a “buy” rating and a $44.00 target price for the company. Oppenheimer upped their target price on Guardian Pharmacy Services from $38.00 to $43.00 and gave the company an “outperform” rating in a research note on Thursday, May 7th. Bank of America increased their price target on Guardian Pharmacy Services from $42.00 to $47.00 and gave the stock a “buy” rating in a report on Wednesday, June 17th. Finally, Weiss Ratings downgraded Guardian Pharmacy Services from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th.

Guardian Pharmacy Services Stock Down 1.9%

GRDN stock opened at $39.54 on Wednesday. Guardian Pharmacy Services has a twelve month low of $19.30 and a twelve month high of $44.00. The stock has a market capitalization of $1.97 billion, a price-to-earnings ratio of 47.64, a price-to-earnings-growth ratio of 2.64 and a beta of 0.05. The firm’s fifty day simple moving average is $39.70 and its two-hundred day simple moving average is $35.85.

Guardian Pharmacy Services (NYSE:GRDN) last announced its earnings results on Wednesday, May 6th. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.05. The business had revenue of $336.60 million for the quarter, compared to the consensus estimate of $329.89 million. Guardian Pharmacy Services had a net margin of 3.64% and a return on equity of 30.72%. The business’s revenue for the quarter was up 2.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.22 earnings per share. As a group, equities research analysts expect that Guardian Pharmacy Services will post 1.18 EPS for the current year.

Institutional Trading of Guardian Pharmacy Services

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Guardian Pharmacy Services during the first quarter valued at $233,000. JPMorgan Chase & Co. grew its holdings in shares of Guardian Pharmacy Services by 48.0% in the second quarter. JPMorgan Chase & Co. now owns 6,027 shares of the company’s stock worth $128,000 after purchasing an additional 1,956 shares during the last quarter. Legal & General Group Plc increased its stake in Guardian Pharmacy Services by 1,783.1% in the 2nd quarter. Legal & General Group Plc now owns 14,895 shares of the company’s stock worth $317,000 after buying an additional 14,104 shares during the period. Rhumbline Advisers increased its stake in Guardian Pharmacy Services by 121.1% in the 2nd quarter. Rhumbline Advisers now owns 16,174 shares of the company’s stock worth $345,000 after buying an additional 8,860 shares during the period. Finally, Quantbot Technologies LP bought a new stake in Guardian Pharmacy Services during the 2nd quarter valued at about $214,000.

Guardian Pharmacy Services Company Profile

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.